Compare TBPH & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | ETON |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 689.8M |
| IPO Year | 2013 | 2018 |
| Metric | TBPH | ETON |
|---|---|---|
| Price | $16.77 | $24.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $18.40 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 402.7K | 373.7K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | N/A |
| EPS | ★ 2.06 | N/A |
| Revenue | $15,386,000.00 | ★ $79,950,000.00 |
| Revenue This Year | $8.46 | $40.90 |
| Revenue Next Year | N/A | $47.23 |
| P/E Ratio | $8.15 | ★ N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $8.33 | $13.09 |
| 52 Week High | $21.03 | $27.29 |
| Indicator | TBPH | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 52.77 |
| Support Level | $13.41 | $16.09 |
| Resistance Level | $17.24 | $27.29 |
| Average True Range (ATR) | 0.41 | 1.03 |
| MACD | 0.02 | -0.50 |
| Stochastic Oscillator | 57.01 | 33.65 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.